title: Should testosterone replacement be offered to hypogonadal men treated previously for prostatic carcinoma?
abstract: Androgen administration can cause prostate cancer progression, and androgen deprivation therapy is a commonly used therapeutic modality in the treatment of prostate cancer. In trying to answer the posed clinical question, this article reviews the risks and benefits of testosterone replacement therapy in this setting and the published data from clinical series. Recommendations are made based on the available evidence.
authors.affiliation: Department of Radiotherapy, Guy's and St Thomas' NHS Foundation Trust, London, UK. david.landau@kcl.ac.uk
authors.forename: D
authors.initials: D
authors.lastname: Landau
authors.forename: T
authors.initials: T
authors.lastname: Tsakok
authors.forename: S
authors.initials: S
authors.lastname: Aylwin
authors.forename: S
authors.initials: S
authors.lastname: Hughes
mesh_terms: D000726:Androgen Antagonists / Q000627:therapeutic use; D020249:Hormone Replacement Therapy; D006801:Humans; D007006:Hypogonadism / Q000188:drug therapy*; D008297:Male; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D013739:Testosterone / Q000627:therapeutic use*
chemical_list: D000726:Androgen Antagonists; D013739:Testosterone; D017430:Prostate-Specific Antigen